Strongest evidence (moderate strength)
Vitamin E shows the most consistent benefits for liver health. In patients with non-alcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), 3 of 5 studies found a small beneficial effect on reducing aspartate aminotransferase (AST) levels, with strongest support at 298–1000 IU/day over 8–12 weeks. For alanine aminotransferase (ALT), all 4 studies reported benefit (3 significant) at 400–1000 IU/day, though effect sizes were mixed (small to moderate). Additionally, 3 studies each found moderate-strength evidence for reduced inflammation (small-to-large effects across clinical populations) and reduced pain (small-to-moderate effects in conditions like fibromyalgia and carpal tunnel syndrome). However, these outcomes carry caveats regarding publication bias and small study numbers.
Mixed or weaker evidence (low to very low strength)
Several outcomes have less robust support. For reducing tumor necrosis factor alpha (TNF-α), only 1 of 3 studies found a benefit (small effect), the other 2 being neutral; the effect may be population-dependent (observed in NASH but not in other groups). Evidence for improved sperm morphology is mixed—1 beneficial study (moderate effect, 300 mg/day for 90 days) but 2 neutral—and for sperm motility, all 3 studies show no benefit (neutral, very low strength). Malondialdehyde levels were reduced in one meta-analysis but not in two individual RCTs. One synthesis on vitamin E levels themselves is inconsistent (mostly neutral).
Effective dose patterns
Doses converge around 298–1000 IU/day for liver enzymes and 400–800 IU/day for TNF-α reduction. The inflammation and pain studies did not consistently report specific effective doses, but one inflammation study used 335 mg/day. The single beneficial sperm morphology study used 300 mg/day (100 mg three times daily). No consistent dosing emerges for weaker outcomes.
Population insights
The most consistent benefits appear in people with NAFLD/MASLD—this population is the focus of the strongest evidence (AST and ALT reductions). Inflammation and pain outcomes were studied in specific clinical groups (e.g., post-surgery, sarcopenia, fibromyalgia) rather than healthy individuals. Fertility studies enrolled men with idiopathic infertility or specific spermatogenic disorders. The benefit for TNF-α and malondialdehyde may be population-specific (NASH and epilepsy, respectively). Generalization to healthy populations is limited.
Notable caveats
Across syntheses, several caveats recur: small evidence bases (only 3–5 studies per outcome), publication bias likely inflating positive results, and many studies failing to reach statistical significance, suggesting true effects may be smaller than reported. Combination supplements (e.g., vitamin E with other nutrients) complicate isolating vitamin E's specific effect in pain and fertility studies. For liver outcomes, the benefit is seen only in NAFLD populations and may not extend to other conditions. These limitations underscore that while promising, the research is preliminary for most outcomes.